In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract  by Neglén, Peter & Raju, Seshadri
In-stent recurrent stenosis in stents placed in the
lower extremity venous outflow tract
Peter Negle´n, MD, PhD, and Seshadri Raju, MD, Jackson, Miss
Purpose: This study was undertaken to describe development of in-stent recurrent stenosis (ISR) in stents placed in the
iliocaval outflow tract and to examine possible contributing factors.
Method: After iliocaval balloon angioplasty and stent insertion to treat chronic nonmalignant obstruction, single-plane
transfemoral venography was performed at least once in 324 limbs, twice in 123 limbs, three times in 40 limbs, and four
times in 4 limbs. ISR was measured with a caliper, and expressed as percentage diameter reduction of patent lumen on the
venograms. Left-right limb ratio was 2.3:1; thrombotic-nonthrombotic disease ratio, 1.2:1; negative-positive thrombo-
philia test ratio, 1.6:1; and above-below inguinal ligament stent placement ratio, 4.5:1. Median stent length was 9 cm
(range, 4-35 cm), and median lumen area before and after stenting was 0.41 cm2 (range, 0-1.65 cm2) and 1.70 cm2
(range, 0.65-4.00 cm2), respectively. Limbs were divided into groups with no ISR, any degree of ISR, greater than 20%
diameter reduction, and greater than 50% diameter reduction. Cumulative ISR and patency rates were analyzed. Possible
contributing factors were examined.
Results: At 42 months, only 23% of limbs demonstrated no ISR. Cumulative rate of limbs with greater than 20% diameter
reduction was 61%, and of limbs with greater than 50% diameter reduction was 15%. Patient gender or sidedness of the
treated extremity did not affect outcome. At 36 months, limbs with thrombotic disease had higher ISR rates than did
limbs without thrombotic disease (63% and 41% of limbs with >20% narrowing, and 23% and 4% of limbs with >50%
narrowing, respectively; P < .01). Similarly, higher rates of ISR were found in patients with thrombophilia and long
stents extending below the inguinal ligament. Primary, assisted primary, and secondary patency rates for the entire
population at 3 years were 75%, 92%, and 93%, respectively. There was a significant increase in ISR in individual limbs,
but analysis of groups of stents did not unequivocally show progression.
Conclusion: Severe (>50%) ISR of iliofemoral venous stents is uncommon over the short term. The three major risk
factors appear to be presence of thrombotic disease, positive thrombophilia test results, and stent extending below the
inguinal ligament (long stents). Although stented limbs that eventually became occluded during the study demonstrated
similar risk factors, no conclusion regarding a cause-effect relationship can be drawn from the present data. Whether late
occlusion is due to acute thrombosis or to gradual development of true intimal hyperplasia requires further study. (J Vasc
Surg 2004;39:181-8.)
Stenting of the iliofemoral venous outflow tract is
emerging as the preferred treatment of venous outflow
obstruction. Several studies have shown encouraging pa-
tency rates and clinical results after stenting to treat
chronic, nonmalignant obstruction of iliac veins over short-
term to intermediate follow-up.1-4 In general, the patency
rate for stents placed in the venous system may be influ-
enced by a variety of factors, such as anatomic location,
cause of obstruction, development of in-stent restenosis
(ISR), amount of venous inflow, and presence of concom-
itant diseases. The reasons for occlusion of venous stents are
not fully understood, and the long-term effects of a stent in
the venous system are unknown. We undertook this study
to describe development of ISR in stents placed in the lower
extremity outflow tract and to evaluate factors that may
influence this process.
MATERIAL AND METHOD
Between December 1997 and July 2001, balloon an-
gioplasty and stenting of the venous outflow tract, includ-
ing the common femoral vein, external and common iliac
veins, or inferior vena cava, was performed in 455 limbs
with chronic, nonmalignant obstruction. Limbs with acute
deep vein thrombosis were excluded, and no patients had
undergone pre-stenting thrombolytic therapy. Stents in 6
patients became occluded in the immediate postoperative
period (30 days). One stent was reopened with catheter-
directed thrombolysis, and remained open 3 months later,
as observed at venography. The other five limbs remained
blocked, precluding any possibility of assessment of devel-
opment of ISR. Data for these limbs were excluded from
that aspect of the study, but were included in calculation of
patency rates.
A single-plane transfemoral venogram was obtained
early (2-3 months) after stenting, again 9 months later, and
annually thereafter as routine surveillance. If the patient
returned with recurrent symptoms, transfemoral venogra-
phy was always used to assess the venous outflow tract. ISR
was assessed as percentage diameter reduction of patent
lumen of the stent on the venogram. The degree of stenosis
was measured with a caliper and calculated as diameter of
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stent diameter of patent area/diameter of stent 100 (%).
Distribution of stenosis in the stent was also noted. At least
one venogram was obtained in 324 limbs (324 of 450,
72%) in 316 patients at 2 to 60 months postoperatively
(median, 5 months; mean, 10  9 [SD]). An additional
venogram was obtained in 123 limbs, two additional
venograms were obtained in 40 limbs, and three additional
venograms were obtained in 4 limbs. These 316 patients
were included in the study. Their median age was 52 years
(range, 14-83 years); 229 were female patients, and 87
were male patients (2.6:1). The right lower limb was
treated in 91 patients, the left limb in 217 patients, and
both limbs in 8 patients (left-right limb ratio 2.3:1 [225:
99]).
The obstructive lesion was considered postthrombotic
(175 limbs in 170 patients) if the patient had a history of
deep vein thrombosis diagnosed with duplex ultrasound
scanning or ascending venography and subsequently
treated with anticoagulation, or findings at venography (eg,
occlusion, stenosis, collateral vessels) or duplex ultrasound
scanning indicative of previous deep vein thrombosis below
the inguinal ligament (direct visualization of thrombus or
indirect indication by partial or total inability to compress
the vein). The remaining 149 limbs in 146 patients were
considered nonthrombotic. Screening for thrombophilia
was performed in 261 of 316 patients (267 limbs), and was
positive for one or more factors in 103 patients (104 limbs).
The screening included determination of levels of proteins
C and S, antithrombin III, anticardiolipin immunoglobulin
IgM and immunoglobulin G, and homocysteine, and de-
tection of lupus anticoagulant, factor V Leiden, and homo-
cysteine gene and prothrombin gene mutation. The test
was positive for one or more factors in 74 of 145 post-
thrombotic limbs (51%), compared with 30 of 122 non-
thrombotic limbs (23%; P  .001, 2 test).
Indications for iliofemoral venous stenting, diagnosis,
and clinical results have been discussed in detail elsewhere,4
and are outside the scope of this article. Technical details of
the intervention have been outlined.5,6 Venous stenting
was performed when more than 50% morphologic stenosis
was found at transfemoral venography or intravascular ul-
trasound (IVUS). Crosscut area of stenosis was measured
with IVUS before and after stenting and compared with the
area of the normal vein below the stenosis.7
Wallstents (Boston Scientific, Natick, Mass) were used
exclusively in the 324 limbs. Stent diameter was 14 to 16
mm in 81% of limbs (264). In most limbs (187, 58%) one
stent was inserted. When two or more stents were inserted
(2 stents in 94 limbs, 29%; and 3 to 6 stents in 43 limbs,
13%), the stents were overlapped by at least 1 cm to ensure
adequate stent cover of the diseased vein without skipped
areas. Median length of the stented vein was 9 cm (range,
4-35 cm). The stent involved the common iliac vein in 307
limbs (95%). In 55% of these 307 limbs (168) stenting was
limited to the iliocaval segment; in 33% (102 limbs) the
lower part of the stent was in the external iliac vein; and in
12% (37 limbs) the stent reached the common femoral
vein. Only two stents were limited to the inferior vena cava,
and 15 stents were placed with the upper end in the external
iliac vein.
For analysis, the limbs were arbitrarily divided into
three groups of similar size, with stent length 4 to 8 cm (n
 100), 9 to 12 cm (n 108), and 13 to 35 cm (n 108).
The stents reached below the inguinal ligament in 59 limbs,
and terminated above the inguinal ligament in 265 limbs.
Only 5 of 59 (8%) limbs with stents below the inguinal
ligament had short stents isolated to the external and
common femoral iliac veins. Most stents placed across the
inguinal ligament (54 of 59, 92%) formed the lower part of
a long stent originating in the common iliac vein or the
inferior vena cava. Consequently the median length of
stented vein was longer in this group compared with the
group with stents ending above the inguinal ligament (18
cm [range, 4-35 cm] vs 9 cm [range, 4-29 cm], respec-
tively; P  .001). The rate of postthrombotic limbs was
greater in those with stenting across the inguinal ligament
compared with above the inguinal ligament (81% vs 48%; P
 .001). Similarly, postthrombotic limbs were overrepre-
sented in the group with longer stents (70% in stented vein
12 cm; Table I).
The median transverse lumen area obtained at IVUS
during the intervention before balloon angioplasty and
stenting was 0.41 cm2 (range, 0-1.65 cm2). For analysis,
limbs were arbitrarily divided into three groups of similar
size, with area 0.0 to 0.30 cm2 (n 91), 0.31 to 0.60 cm2
(n  68), and greater than 0.61 2 (n  67), respectively.
These three groups had similar distribution of thrombotic
and nonthrombotic limbs. After the procedure, median
transverse lumen area was 1.70 cm2 (range, 0.65-2.85
cm2). Similarly, these limbs were also divided into three
groups, with area less than 1.5 cm2 (n  71), 1.50 to 1.85
cm2 (n  80), and greater than 1.85 cm2 (n  70),
respectively.
Statistical analysis was performed with GraphPad Prism
version 3.00 for Windows (GraphPad Software, San Diego,
Calif). To compare groups, a paired or unpaired nonpara-
metric Wilcoxon rank test was used as appropriate. Rates
for primary patency, assisted primary patency (patency after
preemptive intervention), and secondary patency (patency
after intervention for occlusion), as defined by the report-
ing standards of The Society for Vascular Surgery/Interna-
tional Society for Cardiovascular Surgery (ISCVS),8 were
calculated with survival analysis with the Kaplan-Meier
method. Cumulative survival curves were also used to ana-
lyze and compare development of in-stent restenosis. The
log-rank test was used to assess significance between sur-
vival curves and to identify trends of multiple curves. P 
.05 was considered significant.
RESULTS
Thirteen of 324 limbs (4%) became occluded 2 to 30
months (median, 3 months) after the endovascular proce-
dure. Three limbs were successfully recanalized with cath-
eter-directed thrombolysis. Venograms obtained before
and after thrombolysis in these three limbs showed 32%,
33%, and 50% remaining stenosis, respectively. One limb
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had evidence of increasing ISR before occlusion 18 months
after intervention. One limb had a stable ISR of 43% on
several venograms before finally becoming occluded after
49 months. No venogram was obtained in eight limbs
before or after development of occlusion, and therefore
development of ISR could not be assessed. These eight
limbs were excluded from grading of in-stent recurrent
stenosis; thus 316 limbs were study.
To assess development of ISR, limbs were divided into
groups, with no ISR, any degree of ISR, ISR greater than
20% diameter reduction, and ISR greater than 50% diame-
ter reduction. More than 50% recurrence of in-stent steno-
sis was considered severe, inasmuch as this degree of steno-
sis was the indication for stenting in the first place. In 13
limbs, only patency could be ascertained, but degree of ISR
could not be adequately assessed because of poor quality of
venogram. Cumulative ISR rate curves were calculated (Fig
1). At 42 months only 23% of limbs remained ISR-free.
However, many had only minimal narrowing. At the same
interval, 61% of limbs had greater than 20% diameter re-
duction and 15% of limbs had 50% diameter reduction.
Stenosis in the stent most frequently involved the complete
stent uniformly (47%, 143 of 303), sometimes combined
with focal stenosis (6%, 18 of 303). The remaining limbs
had focal stenosis in the common iliac vein segment (24%,
73 of 303) or the external iliac vein segment (16%, 48 of
303), or at the junction of the two segments (7%, 21 of
303).
Several factors with potential to influence development
of ISR were analyzed with cumulative survival (Table I).
Gender did not affect outcome. A similar rate of in-stent
recurrent stenosis was observed in the left and right lower
extremities. In thrombotic limbs ISR developed at a higher
rate than in nonthrombotic limbs (Fig 2). At 36 months
these rates were 63% and 41% in veins with greater than 20%
narrowing, and were 23% and 4% in veins with greater than
50% narrowing in limbs with thrombotic and nonthrom-
botic disease, respectively (P  .01). No difference in
in-stent recurrent stenosis rate was found in comparison of
a subset of right and left limbs with thrombotic or non-
thrombotic obstruction.
In patients positive for thrombophilia, ISR developed
more rapidly than in patients with negative test results (Fig
3). At 36 months of follow-up the rates of ISR greater than
20% were 66% and 42%, respectively, in patients with
positive and negative test results (P  .0005). This differ-
ence was maintained with the rate of limbs with severe
(50%) ISR, but was less pronounced (18% and 12%,
respectively; P  .0247]).
Data concerning length of stented area and placement
below the inguinal ligament appear intimately connected,
and had a similar effect on development of ISR (Table I; Fig
4). The longest stents and those ending below the inguinal
ligament exhibited a rapid increase in ISR during the first 6
months. IRS did not show any preponderance of occur-
rence at the level of the inguinal ligament. There was a
striking difference in the number of limbs with severe
stenosis (50%) at 24 months when limbs with stents
terminating above and below the ligament were compared
(9% and 40%, respectively; P  .0001). Similarly, at 24
Table I. Factors that possibly influence in-stent restenosis rate
Overrepresentation of
limbs with thrombotic
disease
Cumulative
stenosis rate (%)
(20% stenosis)
Cumulative stenosis
rate (%) (50%
stenosis) Month
Gender 36
Male Yes 52 14
Female No 59* 15*
Side 30
Left No 47 8
Right No 49* 20*
Thrombotic disease 36
Present — 63 23
Not present — 41† 4†
Thrombophilia 36
Positive Yes 66 18
Negative No 42† 12‡
Inguinal ligament 24
Above No 44 9
Below Yes 75† 40†
Length (cm) 36
2–8 No 42 5
13–35 Yes 86† 25†
Pre-stent area (cm2) 33
0.00–0.30 No 56 15
0.61 No 37* 8*
Poststent area (cm2) 33
1.50 No 71 23
1.85 No 27§ 5*
Log-rank test: *NS, not significant; †P.001; ‡P.05; §P.001. Frequency of limbs with thrombotic disease was calculated in subgroups and compared with
frequency in total limbs (comparison with 2 test, P .05 considered significant).
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months postintervention, limbs with the longest stents
(13 cm) had ISR 20% in 74% of limbs, as compared
with limbs with intermediate length stents (9-13 cm) and
short stents (4-8 cm): 31% and 15% of limbs, respectively).
The log-rank test for trend was highly significant (P 
.0001). Development of severe ISR (50%) was similar
(Table I). Only 11 of 59 limbs with stents terminating
below the inguinal ligament had nonthrombotic causes. At
12 months, there was no difference in cumulative IRS rate.
All of these nonthrombotic limbs remained patent during
follow-up.
The morphologic cross-cut area of the original obstruc-
tion did not appear to influence development of ISR (Table
I). ISR was more prevalent with smaller cross-cut area
poststenting. At 33 months after intervention, limbs with
the smallest lumen (1.50 cm2) had ISR greater than 20%
in 71% of limbs, as compared with limbs with intermediate
lumen (1.50-1.85 cm 2) and large lumen (1.85 cm 2):
52% and 27%, respectively. The result was mimicked for
severe recurrent stenosis (50%), but did not attain statis-
tical significance. The log-rank test for trend was significant
(P  .0135).
Groups of limbs with multiple venograms at follow-up
without interval interventions were compared to assess
progress of ISR over time (Table II). As a group, there was
no increase in stenosis over time in limbs with three
venograms, although the increase from median degree of
stenosis of 9% to 14% was statistically significant in limbs
with two venograms. In the intervals between venograms 1
and 2 and venograms 2 and 3, degree of ISR increased by
more than 5% in 21% and 13% of limbs, respectively.
Twenty-five secondary endovascular procedures were
performed during follow-up. Limbs treated for IRS were
excluded from analysis of rate and degree of ISR after
intervention, but were included in patency analysis. For the
entire population at 3 years, primary patency rate was 75%,
assisted primary rate was 92%, and secondary patency rate was
93%. Similarly, values for limbs with nonthrombotic and
thrombotic disease at 36 months were 89% and 65%, 100%
and 85%, and 100% and 88%, respectively. Nonthrombotic
limbs had significantly better patency rate compared with
thrombotic limbs (P .035 for primary patency).
It may be of interest to characterize the 13 stented
limbs that became occluded during follow-up. All limbs
had thrombotic disease, with stent length greater than 13
cm, and 9 of 13 limbs had stents terminating below the
inguinal ligament. The iliac veins were completely occluded
or had tight, nonyielding stenoses at balloon angioplasty
Fig 1. Cumulative in-stent restenosis rates for all limbs with any degree of stenosis, greater than 20% narrowing, and
greater than 50% narrowing. Bottom numbers, Total limbs at risk for each time interval (SEM 10%).
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and stenting. Thrombophilia testing yielded positive results
in eight patients and negative results in three patients, and
was not done in two patients. A similar group of patients
also appeared to be at higher risk for development of
significant ISR. Limbs with high risk, that is, with throm-
botic disease, positive thrombophilia test results, and stent
placement below the inguinal ligament (n  19) were
compared with limbs with low risk, that is, without throm-
botic disease or stent placement below the ligament and
negative for thrombophilia (n  85). At 24 months
postintervention, limbs at high risk had ISR 20% and
severe stenosis (50%) to a greater degree, compared with
limbs at low risk (77% and 61% vs 19% and 0%, respec-
tively).
Table II. Development of in-stent restenosis in 111 limbs with two subsequent venograms and in 32 limbs with three
subsequent venograms
Venogram 1 Venogram 2 Venogram 3
Median Range Median Range Median Range
111 Limbs
Months after intervention 5 1–32 16 0–95
In-stent restenosis (%) 9 0–63 14 0–95*
32 limbs
Months after intervention 5 2–31 14 3–37 26 3–60
In-stent restenosis (%) 19 0–31 18 0–65† 18 0–80‡
*P  .0014 compared with venogram 1.
†P  .1763 compared with venogram 1 (not significant).
‡P  .3591 compared with venogram 1 (not significant).
Fig 2. Cumulative in-stent restenosis rates for limbs with thrombotic (PT) and nonthrombotic (non-PT) disease with
greater than 20% and greater than 50% stenosis, respectively. Bottom numbers, Total limbs at risk for each time interval
(SEM 10%).
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 1 Negle´n and Raju 185
DISCUSSION
To our knowledge, the rate of ISR in stents placed in
the venous outflow of the lower extremities to treat
chronic, nonmalignant obstruction has not previously been
described. In this study ISR developed to some degree in
most stents (80% at 42 months). Only a few (17%) had
severe (50%) stenosis during the first 3 years. Measure-
ment of degree of in-stent stenosis as diameter reduction on
single-plane venograms may, however, underestimate the
degree of intrastent stenosis.7 The optimal assessment
would be to use IVUS to directly measure wall thickness,
total area of stenosis, and any vessel remodeling that may
have occurred. Cost and logistics prevented regular use of
IVUS, and it was performed in only a few patients sched-
uled for a secondary procedure. The nature of ISR is not
known. It may be a lining of thrombosis or a true reaction
of the vessel wall, with formation of neointimal hyperplasia
as observed in stented arteries.9 Early in this series, a few
patients with early significant ISR underwent thrombolysis
in an effort to dissolve any thrombus. These attempts were
all unsuccessful. Invariably, balloon angioplasty of in-stent
stenosis revealed a very hard stenosis that was difficult to
dilate. Any improvement in lumen size appeared to be
secondary to remodeling rather than to true decrease in
wall thickness. These clinical observations indicate that the
reaction to stenting of the vein is possibly a cellular response
rather than formation of thrombosis.
As expected, gender and treated limb side did not
influence development of ISR. Conversely, the presence of
chronic thrombotic disease, as indicated by history or mor-
phologic findings, anywhere in the involved lower extrem-
ity resulted in a high rate of ISR. Severe stenosis (50%)
developed in the stent in 23% of these extremities, as
compared with 4% of nonthrombotic limbs. This strong
impact of thrombotic disease on development of ISR ap-
pears to be reflected in the analysis of other potential
contributing factors. There was an overrepresentation of
limbs with thrombotic disease in patients with thrombo-
philia, stents terminating below the inguinal ligament, and
long stents. Thus a higher rate of ISR was found in patients
positive for thrombophilia, which was also more frequently
seen in limbs with previous thrombotic disease. The high
recurrent stenosis rate in limbs with long stents, especially
stents extending below the inguinal ligament, may reflect
treatment of more severe and extensive disease demon-
strated in limbs with thrombotic disease.10 A higher rate of
chronic thrombotic obstruction was also observed in these
limbs.
Fig 3. Cumulative in-stent restenosis rates for limbs with greater than 20% and greater than 50% stenosis, respectively, in
patients positive and negative for thrombophilia. Bottom numbers, Total limbs at risk for each time interval (SEM10%).
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It may have been expected that when a narrow vessel is
markedly dilated, injury to the vessel wall will be greater
and will lead to greater reaction from the stented wall.
However, there was no increased rate of recurrent stenosis
in stented vessels with tight pre-stenting stenosis. The
increased rate of ISR in stents with smaller lumen after
dilation may result because the same degree of wall thick-
ening will have a relatively greater effect in a smaller stented
vessel compared with a larger vessel. The rate of severe
stenosis (50%), however, was not significantly different.
It is unclear from our data whether there is continuous
progress of ISR over time. Despite the fact that groups of
limbs with multiple follow-up venograms did not unequiv-
ocally exhibit an increase in stenosis, no doubt there is
significant progress in individual cases.
The three major risk factors for development of severe
ISR appear to be presence of thrombotic disease, positive
results of thrombophilia test, and placement of long stents
terminating below the inguinal ligament. At 24 months
poststenting, limbs with these risk factors demonstrated a
61% rate of severe ISR, whereas no ISR developed in the
absence of these risk factors. Although stented limbs that
eventually became occluded during this study had similar
risk factors, no conclusion regarding a cause-effect relation-
ship can be drawn from the present data. Whether late
occlusion occurs as a result of acute recurrent thrombosis or
gradual development of true intimal hyperplasia requires
further study.
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CORRECTIONS
In: Brown OW, Medicolegal implications of board certification (J Vasc Surg 2003;38:407-8).
The Editors would like to clarify that the author, O. William Brown, MD, JD, is the defendant in the case described in the Editorial.
In: Lauder C, Kelly A, Thompson MM, London NJM, Bell PRF, Naylor AR. Early and late outcome after carotid artery
bypass grafting with saphenous vein (J Vasc Surg 2003;38:1025-30).
On page 1030 of the Lauder article, the last line should read, “See Invited Commentary on page 1038.”
In: Camiade C, Maher A, Ricco J-B, Roumy J, Febrer G, Marchand C, et al. Carotid bypass with polytetrafluoroethylene
grafts: A study of 110 consecutive patients (J Vasc Surg 2003;38:1031-8).
The last line on page 1037 of Camiade et al should read, “See Invited Commentary on page 1038.”
In: Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, et al. P-selectin and leukocyte
microparticles are associated with venous thrombogenesis (J Vasc Surg 2003;38:1075-89).
The Myers et al article contains the following errors:
The legend for Fig 5 should read, “. . .shams at day 6 include. . .^CT(23.7 ng/mg).” Under “*CT vs WT, PKO, EPKO P.05,”
Fig 5 B should include, “**WT vs PKO, EPKO P.01.”
A double asterisk should appear above the column PKO(n5) in Fig 6 A.
On page 1084, column one, the text should read, “PKO animals demonstrated significantly reduced levels of E-selectin at day 2
compared with WT (P.01) and nonsignificant reduced levels at day 6 (706 64 vs 1168 312 pg/mg total protein; P.15, ns).
On page 1085, column 2, the text should read, “However, Ab-PSGL-1 did result in a statistically significant decline at day 2 (33
2 to 23  1 ng/mg total protein, P  .01) and no decline at day 6 (24  5 to 26  2 ng/mg total protein, ns).
An incorrect version of Fig 8 B was submitted for publication. The following is the correct figure:
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